Market Cap 411.64B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.58
Forward PE 21.82
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 4,283,600
Avg Vol 6,037,346
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 57%
Beta 0.50
Analysts Strong Sell
Price Target $244.54

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
PrivateProfiteering
PrivateProfiteering Nov. 21 at 2:06 AM
$ABBV: The last close at $229.93 indicates a strong position within its recent trading range. With an RSI of 67.01, the stock is approaching overbought territory, suggesting a potential pullback. The 30-day MA at $226.77 and the 50-day MA at $226.39 provide support levels, indicating a bullish trend in the short term. The 60-day high of $244.81 sets a target for upward momentum, while the low of $205.49 establishes a solid floor for risk management. Directional bias: Slightly bullish, but caution is warranted due to the high RSI. Suggested entry: $229.00 (on a slight pullback). Stop: $225.00 (below the 30-day MA). Targets: $240.00 (first target) and $244.00 (second target, near the 60D high). Monitor for potential reversal signals as the stock approaches overbought conditions. https://privateprofiteers.com
0 · Reply
TechTraderGrok
TechTraderGrok Nov. 21 at 12:19 AM
Bought $ABBV at $229.45. From Grok: "Uptrend confirmed (price>EMA>SMA, both rising), bouncing off rising supports at $216-220 post-earnings dip with bullish MACD/RSI neutral; favorable R/R targeting $235 resistance. Next earnings ~Jan 31, 2026; no catalysts next 3 days." https://www.techtrader.ai/grokwall/?post=15613&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Iightning
Iightning Nov. 20 at 11:12 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 10:54 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $227.50 Put · NOV 28, 2025 Exp Entry Price: $2.38 - $2.45 Exit Price Target: $3.58 Profit Margin: +46% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
TechTraderGrok
TechTraderGrok Nov. 20 at 10:06 PM
Bought $ABBV at $229.81. From Grok: "Entering long ABBV in confirmed uptrend with price above rising EMA/SMA, positive MACD crossover signaling momentum, recent bounce from $212 support amid pharma sector strength and no imminent catalysts, targeting multi-week hold towards $235 resistance." https://www.techtrader.ai/grokwall/?post=15600&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
danieldanielecki
danieldanielecki Nov. 20 at 8:10 PM
$ABBV overvalued
0 · Reply
Czreri1
Czreri1 Nov. 20 at 5:22 PM
$ABBV here comes the rotation from tech
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 20 at 3:52 PM
$SLS $ABBV $RHHBY Spent a S Ton of Cash on the Failed VIALE-M Phase 3 Trial. - " The Primary end point is relapse free survival. Secondary outcomes include Over all Survival, mrd conversion, and improvement in QoL." - Meanwhile we are SEEING Unheard of Near Miraculous Median Overall Survival in ALL POOLED - SLS P3 Patients - ALL POOLED - Control on AzaVEN and Gps Immunotherapy Patients. You can Link to NCT Results - Terminated due to Toxicity. Aza+VEN is the BEST Available Treatment for the SLS REGAL Phase 3 Control ARM Patients - and it FAILED. Aza+VEN also Failed the VERONA Phase 3 AML precursor MDS Trial. and Aza+VEN Failed the VIALE-T Phase 3 Trial for AML patients Post Transplant, due to toxicity and patient death. https://www.tandfonline.com/doi/full/10.2217/fon-2022-0450?src=recsys
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 20 at 9:53 AM
$ABBV Share Price: $232.83 Contract Selected: Dec 12, 2025 $235 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.26 – $7.65 Potential Upside: 68% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 6:56 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 28, 2025 Exp Entry Price: $3.54 - $3.72 Exit Price Target: $7.26 Profit Margin: +105% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Latest News on ABBV
AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 8 days ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 8 days ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 12 days ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 19 days ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 20 days ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 20 days ago

AbbVie: Why Q3 Confirms Its Immunology Dominance


AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 20 days ago

AbbVie Lifts Profit Outlook as Sales Rise


AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 20 days ago

AbbVie Reports Third-Quarter 2025 Financial Results


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 22 days ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH


AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 23 days ago

AbbVie: Deep Discount Before Earnings


AbbVie expects $2.7 billion R&D charge in third quarter

Oct 3, 2025, 4:16 PM EDT - 6 weeks ago

AbbVie expects $2.7 billion R&D charge in third quarter


AbbVie: Wins Accumulating While We Wait For Next BD Steps

Oct 3, 2025, 11:05 AM EDT - 6 weeks ago

AbbVie: Wins Accumulating While We Wait For Next BD Steps


ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 7 weeks ago

ABBV Stock vs. Eli Lilly & Merck

LLY MRK


AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Oct 2, 2025, 8:00 AM EDT - 7 weeks ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call


Natrelle® Awarded Supplier Agreement from Vizient

Oct 1, 2025, 8:00 AM EDT - 7 weeks ago

Natrelle® Awarded Supplier Agreement from Vizient


AbbVie For Healthy Dividend Growth

Sep 27, 2025, 7:00 AM EDT - 7 weeks ago

AbbVie For Healthy Dividend Growth


PrivateProfiteering
PrivateProfiteering Nov. 21 at 2:06 AM
$ABBV: The last close at $229.93 indicates a strong position within its recent trading range. With an RSI of 67.01, the stock is approaching overbought territory, suggesting a potential pullback. The 30-day MA at $226.77 and the 50-day MA at $226.39 provide support levels, indicating a bullish trend in the short term. The 60-day high of $244.81 sets a target for upward momentum, while the low of $205.49 establishes a solid floor for risk management. Directional bias: Slightly bullish, but caution is warranted due to the high RSI. Suggested entry: $229.00 (on a slight pullback). Stop: $225.00 (below the 30-day MA). Targets: $240.00 (first target) and $244.00 (second target, near the 60D high). Monitor for potential reversal signals as the stock approaches overbought conditions. https://privateprofiteers.com
0 · Reply
TechTraderGrok
TechTraderGrok Nov. 21 at 12:19 AM
Bought $ABBV at $229.45. From Grok: "Uptrend confirmed (price>EMA>SMA, both rising), bouncing off rising supports at $216-220 post-earnings dip with bullish MACD/RSI neutral; favorable R/R targeting $235 resistance. Next earnings ~Jan 31, 2026; no catalysts next 3 days." https://www.techtrader.ai/grokwall/?post=15613&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Iightning
Iightning Nov. 20 at 11:12 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 10:54 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $227.50 Put · NOV 28, 2025 Exp Entry Price: $2.38 - $2.45 Exit Price Target: $3.58 Profit Margin: +46% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
TechTraderGrok
TechTraderGrok Nov. 20 at 10:06 PM
Bought $ABBV at $229.81. From Grok: "Entering long ABBV in confirmed uptrend with price above rising EMA/SMA, positive MACD crossover signaling momentum, recent bounce from $212 support amid pharma sector strength and no imminent catalysts, targeting multi-week hold towards $235 resistance." https://www.techtrader.ai/grokwall/?post=15600&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
danieldanielecki
danieldanielecki Nov. 20 at 8:10 PM
$ABBV overvalued
0 · Reply
Czreri1
Czreri1 Nov. 20 at 5:22 PM
$ABBV here comes the rotation from tech
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 20 at 3:52 PM
$SLS $ABBV $RHHBY Spent a S Ton of Cash on the Failed VIALE-M Phase 3 Trial. - " The Primary end point is relapse free survival. Secondary outcomes include Over all Survival, mrd conversion, and improvement in QoL." - Meanwhile we are SEEING Unheard of Near Miraculous Median Overall Survival in ALL POOLED - SLS P3 Patients - ALL POOLED - Control on AzaVEN and Gps Immunotherapy Patients. You can Link to NCT Results - Terminated due to Toxicity. Aza+VEN is the BEST Available Treatment for the SLS REGAL Phase 3 Control ARM Patients - and it FAILED. Aza+VEN also Failed the VERONA Phase 3 AML precursor MDS Trial. and Aza+VEN Failed the VIALE-T Phase 3 Trial for AML patients Post Transplant, due to toxicity and patient death. https://www.tandfonline.com/doi/full/10.2217/fon-2022-0450?src=recsys
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 20 at 9:53 AM
$ABBV Share Price: $232.83 Contract Selected: Dec 12, 2025 $235 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.26 – $7.65 Potential Upside: 68% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 6:56 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 28, 2025 Exp Entry Price: $3.54 - $3.72 Exit Price Target: $7.26 Profit Margin: +105% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 20 at 6:09 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $20.81- $25.44 Scale out: $80.94-$138.75 Profit Potential : 268% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
RunnerSignals
RunnerSignals Nov. 20 at 4:34 AM
$ABBV slow and steady wins. the long-term compounding story stays intact. dips still look like accumulation zones for patient traders
0 · Reply
Iightning
Iightning Nov. 19 at 8:47 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 19 at 8:43 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · NOV 28, 2025 Exp Entry Price: $2.95 - $3.05 Exit Price Target: $5.72 Profit Margin: +94% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 19 at 6:41 PM
$SLS The Aza+VEN Viale-M - AML Maintenance Phase 3 Trial for Primary Remission Patients CR1, conducted by $ABBV $RHHBY and $BMY FAILED. It was a 2 Part Trial, initial stage to identify ideal dosing, with multiple options, - failed to find a non toxic dose of Aza+VEN Oral too, for AML CR1 Maintenance. Aza+VEN is the BAT / Best Available Treatment for the REGAL Control Arm AML CR2 Patients. Meanwhile we are seeing near Miraculous Survival in the ALL Pooled Data. . . .
0 · Reply
LionsFan777
LionsFan777 Nov. 19 at 3:28 PM
$ABBV, $AVGO, $TSLA Nice morning !
0 · Reply
ZacksResearch
ZacksResearch Nov. 19 at 2:11 PM
$ABBV is bouncing back — but is this rebound strong enough to trust? The teaser shows the stock recovering from its Q3 dip as immunology and neuroscience strength help counter Humira erosion and softness in aesthetics. A real push-pull setup for investors. Full buy/hold/sell breakdown here 👉 https://www.zacks.com/stock/news/2792944/abbvie-stock-rebounds-after-q3-dip-time-to-buy-hold-or-sell?cid=sm-stocktwits-2-2792944-teaser-21586&ADID=SYND_STOCKTWITS_TWEET_2_2792944_TEASER_21586
0 · Reply
ZacksResearch
ZacksResearch Nov. 19 at 1:11 PM
$ABBV: Is the recent surge a buying signal or a false dawn? 📈 🔥 Sales rose 9.1% in Q3 2025, and the company raised 2025 guidance for the third time, driven by Skyrizi and Rinvoq's stellar performance. Yet, stock dipped post-earnings due to softer oncology sales and continued aesthetics weakness. Discover if ABBV's momentum can continue 👉 https://www.zacks.com/stock/news/2792944/abbvie-stock-rebounds-after-q3-dip-time-to-buy-hold-or-sell?cid=sm-stocktwits-2-2792944-body-21584&ADID=SYND_STOCKTWITS_TWEET_2_2792944_BODY_21584
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 19 at 7:20 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $21.43- $26.19 Scale out: $83.34-$142.88 Profit Potential : 399% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Iightning
Iightning Nov. 19 at 5:19 AM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 19 at 2:51 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 28, 2025 Exp Entry Price: $2.47 - $3.40 Exit Price Target: $4.35 Profit Margin: +76% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 18 at 9:42 PM
$SLS FACTS: BAT for Control ARM patients Failed 3 Large Phase 3 Trials conducted by $ABBV $RHHBY $BMY - GPs Achieved Statistically Significant 21 Month MOS - in an older (74), All MRD+ (Sicker) Phase 2 Trial Setting. Gps Phase Patients will also recieve 15 treatments in year 1 and 6 in year 2 and 4 in year 3 and beyond vs only 6-12 in year 1 in the P2. GPS Elicited a 64% Immune Response rate in the P2, its 80% in the P3 per the IDMC unblinded Interim Data. Ir is Directly Correlated with increased Survival. -- GPS P 3 Patients will have a Longer MOS than the 21 month P2. - IDMC unblinded P3 Interim ALL Pooled n.y.m >13.5. - 128 P3 Enrollment Completed 20 months ago 105 of the 128 Enrolled Nov 2023 are in Trial AT Least 24 months. - There are several Published AML CR2 Trial Results for BAT, w NIL Surviving Past 20 months - only the rarest of rare Control Arm patients on BAT Remain Alive past 20 months. There +/- 60 Patient EVENTS Just from the Control ARM and we have yet to See 80. ...
0 · Reply